ArticleDiseases (Basel, Switzerland)2026
Locked-Window EQ-5D-5L (Index and VAS) Benchmarking in Sarcoma Care: Rule-Based Traffic-Light Classification Across Two Institutions.
Article in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundValue-based sarcoma care requires outcome measures that reflect the patient perspective; however, many sarcoma episodes begin with near-normal function and undergo necessary morbidity for oncologic control, making simple "improvement" an unreliable proxy of value. In routine care, patient-reported outcome data are often irregular and incomplete, limiting benchmarking and learning across institutions. We therefore developed a rule-based EQ-5D-5L (index and VAS) traffic-light framework and evaluated its feasibility and benchmarking signal in two institutions.
methodsWe performed a retrospective, two-institution cohort analysis of 729 malignant and intermediate episodes, defined using a prespecified histology behavior mapping. PROM evaluation was anchored to a hierarchical T0 (index surgery date; if unavailable, radiotherapy start date; if unavailable, systemic therapy start date where a valid and interpretable start date was available). EQ-5D-5L index and EQ-VAS were assigned to prespecified locked windows: baseline (-90 to +14 days preferred; +15 to +90 days fallback), 12 months (180-365 days; target 270), and 24 months (660-820 days; target 730). A rule-based traffic-light classification was applied at 12 and 24 months (RED if index < 0.75 or VAS < 50; GREEN if index ≥ 0.85 and VAS ≥ 70; otherwise YELLOW). PROM evaluability was defined as the availability of at least one valid EQ-5D-5L index and/or EQ-VAS value within each window.
resultsPROM evaluability in locked windows was feasible but incomplete. Baseline PROMs were available for 107/729 episodes (14.7%), 12-month PROMs for 119/729 (16.3%), and 24-month PROMs for 84/729 (11.5%). At 12 months, evaluable episodes included 75 from Institution A and 44 from Institution B; at 24 months, 56 and 28, respectively. Traffic-light outputs showed heterogeneity at both timepoints and clearer cross-institution difference at 24 months than at 12 months. At 12 months, the distribution was predominantly GREEN in both institutions (Institution A: 73.3% GREEN, 9.3% YELLOW, 17.3% RED; Institution B: 65.9% GREEN, 18.2% YELLOW, 15.9% RED;
conclusionsA prespecified EQ-5D-5L (index and VAS) traffic-light framework anchored by hierarchical T0 and evaluated in locked windows yields interpretable patient-perspective benchmarking signals in real-world sarcoma care. The approach was operationally feasible within the evaluable subset and appeared more discriminative at 24 months than at 12 months, while incomplete PROM capture remains a major implementation limitation for representative and reliable network-scale benchmarking and learning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.